Caribou Biosciences
Brian Francica is a Senior Scientist 2 at Caribou Biosciences, responsible for leading preclinical research and translational development for the CB-012 project, focusing on next-generation CAR T strategies. Prior experience includes roles at Tempest, where leadership in preclinical research supported projects through to IND submission and enhanced understanding of clinical-stage programs. As a Scientist II at Aduro Biotech, Brian contributed to translational science and immunology, developing preclinical models and conducting research for drug candidate nomination. An early career at Johns Hopkins School of Medicine involved investigating immunotherapy mechanisms, culminating in a Ph.D. in Immunology, following a Bachelor’s degree in the same field from the University of Virginia.
Caribou Biosciences
2 followers
Caribou Biosciences is a leading clinical-stage CRISPR genome editing biotechnology company founded by pioneers of CRISPR biology and located in Berkeley, CA. The company is developing an internal pipeline of off-the-shelf, genome-edited CAR-T and natural killer (NK) cell therapies.